Accipiter Biosciences

Accipiter Biosciences is a private, preclinical-stage biotech leveraging computational protein design to create novel, multifunctional agonist biologics. Founded in 2018 by alumni of the University of Washington's Institute for Protein Design, the company has raised $12.7 million in seed funding from a syndicate co-led by Takeda and Flying Fish Partners. Accipiter is advancing its internal pipeline in autoimmunity and oncology while also engaging in strategic partnerships with major pharmaceutical companies like Pfizer and Kite Pharma to expand its platform capabilities.

Proprietary computational protein design platform using machine learning and advanced modeling to create de novo, multifunctional protein biologics that act as agonists, engaging multiple cell-surface receptors simultaneously. Enables rapid design-to-test cycles in under two months.

Accipiter competes in the crowded fields of autoimmune and oncology biologics, facing competition from large pharma and biotech companies developing antibodies, multispecifics, and other protein therapeutics. Its unique differentiator is the focus on de novo designed agonist proteins that activate multiple pathways. Key competitors include other computational protein design companies (e.g., those spun out from the Institute for Protein Design) and firms developing cytokine agonists or engineered protein therapies.